| Vidya B Yalamanchi, MD | |
|
200 Medical Center Dr, Hazard, KY 41701-9466 | |
| (606) 487-7510 | |
| (606) 439-6793 |
| Full Name | Vidya B Yalamanchi |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 47 Years |
| Location | 200 Medical Center Dr, Hazard, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053351833 | NPI | - | NPPES |
| 64248941 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 24895 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hazard Arh Regional Medical Center | Hazard, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Appalachian Regional Healthcare Inc. | 0840107835 | 232 |
News Archive
Hundreds of mutations exist in leukemia cells at the time of diagnosis, but nearly all occur randomly as a part of normal aging and are not related to cancer, new research shows.
EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that the Phase III STARTa trial of its investigational product L-BLP25 (formerly referred to as Stimuvax) in patients with unresectable, locally advanced stage IIIA or IIIB non-small cell lung cancer (NSCLC) did not meet its primary endpoint to demonstrate a statistically significant improvement in overall survival (OS).
Despite the fact that they both infect the liver, the hepatitis A and hepatitis C viruses actually have very little in common.
A trial beginning next week targeting the nation's largest health insurer and its California subsidiary for allegedly automatically denying requests for out-of-network liver transplants will help shed light on the need for stronger health reform than is currently being considered, according to Consumer Watchdog. The group urged President Obama, White House representatives, and the national news media to follow the trial.
› Verified 5 days ago
| Entity Name | Appalachian Regional Healthcare Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528148012 PECOS PAC ID: 0840107835 Enrollment ID: O20031125000520 |
News Archive
Hundreds of mutations exist in leukemia cells at the time of diagnosis, but nearly all occur randomly as a part of normal aging and are not related to cancer, new research shows.
EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that the Phase III STARTa trial of its investigational product L-BLP25 (formerly referred to as Stimuvax) in patients with unresectable, locally advanced stage IIIA or IIIB non-small cell lung cancer (NSCLC) did not meet its primary endpoint to demonstrate a statistically significant improvement in overall survival (OS).
Despite the fact that they both infect the liver, the hepatitis A and hepatitis C viruses actually have very little in common.
A trial beginning next week targeting the nation's largest health insurer and its California subsidiary for allegedly automatically denying requests for out-of-network liver transplants will help shed light on the need for stronger health reform than is currently being considered, according to Consumer Watchdog. The group urged President Obama, White House representatives, and the national news media to follow the trial.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Vidya B Yalamanchi, MD 200 Medical Center Dr, Hazard, KY 41701-9466 Ph: (606) 487-7510 | Vidya B Yalamanchi, MD 200 Medical Center Dr, Hazard, KY 41701-9466 Ph: (606) 487-7510 |
News Archive
Hundreds of mutations exist in leukemia cells at the time of diagnosis, but nearly all occur randomly as a part of normal aging and are not related to cancer, new research shows.
EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that the Phase III STARTa trial of its investigational product L-BLP25 (formerly referred to as Stimuvax) in patients with unresectable, locally advanced stage IIIA or IIIB non-small cell lung cancer (NSCLC) did not meet its primary endpoint to demonstrate a statistically significant improvement in overall survival (OS).
Despite the fact that they both infect the liver, the hepatitis A and hepatitis C viruses actually have very little in common.
A trial beginning next week targeting the nation's largest health insurer and its California subsidiary for allegedly automatically denying requests for out-of-network liver transplants will help shed light on the need for stronger health reform than is currently being considered, according to Consumer Watchdog. The group urged President Obama, White House representatives, and the national news media to follow the trial.
› Verified 5 days ago
Dr. Raymond Elsoueidi, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 200 Medical Center Dr, Hazard, KY 41701 Phone: 606-439-6600 | |
Dr. Gregory Balabanian, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 200 Medical Center Dr, Hazard, KY 41701 Phone: 606-487-7510 Fax: 606-439-6793 | |
Dr. Thomas E. Karelis Jr., MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 311 Roy Campbell Dr, Hazard, KY 41701 Phone: 606-487-0776 Fax: 606-487-0777 | |
Dr. Jeffery Prater, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 271 E Main St, Hazard, KY 41701 Phone: 606-439-1316 Fax: 606-439-3922 | |
Dr. Samuel Dean Bailey, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 200 Medical Center Dr, Hazard, KY 41701 Phone: 606-487-7902 | |
Mr. Ionut Stefanescu Sturz, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 311 Roy Campbell Drive, Hazard, KY 41701 Phone: 606-487-0776 Fax: 606-487-0777 |